Luspatercept 改善 β 地中海贫血患者血红蛋白水平及输血需求的研究
该开放标签、非随机、非对照研究纳入 64 例 β 地中海贫血患者,评估 Luspatercept 改善贫血及疾病并发症的效果。58% 的非输血依赖患者(接受较高剂量 0.6-1.25 mg/kg)血红蛋白较基线平均升高≥1.5 g/dL 持续≥14 天,81% 的输血依赖患者红细胞输血负荷降低≥20%。
要点
- 非输血依赖患者中 58% 接受 0.6-1.25 mg/kg 者血红蛋白较基线平均升高≥1.5 g/dL 持续≥14 天。
- 输血依赖患者中 81% 实现红细胞输血负荷较治疗前 12 周降低≥20%。
- 最常见 1-2 级不良事件为骨痛、头痛和肌痛。
核心结论
- 接受 Luspatercept 的 β 地中海贫血患者中高比例出现血红蛋白或输血负荷改善,这些发现支持开展随机临床试验评估疗效与安全性。
研究设计与样本
- 开放标签、非随机、非对照研究,包括 24 周剂量探索与扩展阶段(初始阶段)及目前仍在进行的 5 年扩展阶段。
- 共纳入 64 例患者,其中 33 例为非输血依赖(平均血红蛋白<10.0 g/dL,每 8 周输血<4 单位红细胞),31 例为输血依赖(每 8 周≥4 单位红细胞)。
- 患者每 21 天皮下注射 Luspatercept 0.2 至 1.25 mg/kg 至少 5 个周期(剂量探索阶段),扩展队列及 5 年扩展阶段剂量为 0.8 至 1.25 mg/kg。
主要发现
- 18 例接受较高剂量水平(0.6-1.25 mg/kg)的非输血依赖患者(58%)实现血红蛋白较基线平均升高≥1.5 g/dL 持续≥14 天。
- 26 例输血依赖患者(81%)实现红细胞输血负荷降低≥20%。
- 截至数据截止时,33 例患者仍在研究中。
关键数值与推荐
- 主要终点为红系反应:非输血依赖患者血红蛋白较基线升高≥1.5 g/dL 持续≥14 天(无红细胞输注),或输血依赖患者红细胞输血负荷较治疗前 12 周降低≥20%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
β-thalassemia is a hereditary disorder with limited approved treatment options; patients experience anemia and its complications, including iron overload. The study aim was to determine whether luspatercept could improve anemia and disease complications in patients with β-thalassemia. This open-label, nonrandomized, uncontrolled study consisted of a 24-week dose-finding and expansion stage (initial stage) and a 5-year extension stage, currently ongoing. Sixty-four patients were enrolled; 33 were non-transfusion dependent (mean hemoglobin, <10.0 g/dL; <4 red blood cell [RBC] units transfused per 8 weeks), and 31 were transfusion dependent (≥4 RBC units per 8 weeks). Patients received 0.2 to 1.25 mg/kg luspatercept subcutaneously every 21 days for ≥5 cycles (dose-finding stage) and 0.8 to 1.25 mg/kg (expansion cohort and 5-year extension). The primary end point was erythroid response, defined as hemoglobin increase of ≥1.5 g/dL from baseline for ≥14 consecutive days (without RBC transfusions) for non-transfusion-dependent patients or RBC transfusion burden reduction ≥20% over a 12-week period vs the 12 weeks before treatment for transfusion-dependent patients. Eighteen non-transfusion-dependent patients (58%) receiving higher dose levels of luspatercept (0.6-1.25 mg/kg) achieved mean hemoglobin increase ≥1.5 g/dL over ≥14 days vs baseline. Twenty-six (81%) transfusion-dependent patients achieved ≥20% reduction in RBC transfusion burden. The most common grade 1 to 2 adverse events were bone pain, headache, and myalgia. As of the cutoff, 33 patients remain on study. In this study, a high percentage of β-thalassemia patients receiving luspatercept had hemoglobin or transfusion burden improvements. These findings support a randomized clinical trial to assess efficacy and safety. This study was registered at www.clinicaltrials.gov as #NCT01749540 and #NCT02268409.
引用
- Piga A, Perrotta S, Gamberini MR, et al. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia. Blood. 2019. PMID: 30617198. doi:10.1182/blood-2018-10-879247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。